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Abstract
Background
In sub-Saharan Africa, the hepatitis B virus (HBV) and human immunodeficiency virus (HIV)
infections are endemic. Although there has been great progress in HIV care, universal HBV
vaccination and care is lacking. In this study, we aimed to determine the prevalence of HBV,
HBV genotypes, and drug resistance mutations in dual infected cases in a cohort of HIV
patients in Northwest Ethiopia.
Methods
A total of 308 HIV-1 positive patients were enrolled into the study and tested for HBsAg in
plasma. In HBsAg positive samples, HBV DNA was analyzed for HBV genotype using in-
house nested PCR with HBV-specific pre-core / core or surface primers, and for HBV drug
resistance mutations (DRMs) in polymerase region. Odds ratio at 95% confidence interval
was calculated.
Results
Of the 308 HIV-positive subjects, 62.7% were female, median age 38 years (range 18–68,
IQR: 27–49), and the median CD4 count 405 cells/μl (IQR: 75–734). Overall, 94.2% were on
antiretroviral therapy (ART) frequently with combinations of Zidovudine (AZT)- Lamivudine
(3TC)—Nevirapine (NVP). HBsAg was detected in 5.5% (95%CI 2.95–8.08%) of the study
participants, of which the majority were infected with HBV genotype A (7A, 2E, 2D, 1C,
1 G). All HIV/HBV positive cases were on ART with anti-HBV activity (i.e., 3TC) and 3TC
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associated HBV DRMs (i.e., rtV173L, rtL180M, and rtM204V) were detected in 7/13 (53.8%)
subjects.
Conclusion
In this cross-sectional study of HIV-infected individuals, we found 5.5% HBV/HIV co-
infected cases. Most were receiving the first generation anti-HBV therapy with a low genetic
barrier to resistance, and several carried mutations associated with anti-HBV (3TC) drug
resistance. These data underscore the importance of integrating HBV screening to the HIV
treatment guidelines for better management and prevention of HBV-related liver disease.
Introduction
The Hepatitis B virus (HBV) is a major global public health problem. According to the World
Health Organization (WHO), more than 240 million people are hepatitis B surface antigen
(HBsAg) positive chronic HBV (CHB) carriers and are at risk of developing serious liver dis-
eases such as cirrhosis and hepatocellular carcinoma (HCC) [1, 2]. The prevalence of CHB
greatly varies worldwide (0.5%-20%), with the greatest burden of disease in Southeast Asia and
Sub-Sahara Africa [2, 3]. Persons living with HIV have a disproportionate high burden of
HBV infection because of shared risk factors, transmission modes and endemicity [2–4]. Of
36.7 million HIV-infected people, approximately 10% have CHB. HIV increases mortality
from cirrhosis and end-stage liver disease in HBV co-infection [5–7]. The estimated liver-
related mortality rate in HBV/HIV co-infected patients was 14.2 per 1000 persons-years, while
the rate in HBV or HIV mono-infected ones were only 0.8 and 1.7 per 1000 persons-years
respectively [8].
In sub-Sahara Africa, HBV infection status of most HIV patients is unknown. Hence, HBV/
HIV co-infected patients are often treated with lamivudine (3TC) as the only anti-HBV active
agent. In CHB, treatment with first generation nucleos(t)ide analog (NA) (i.e., 3TC) leads to
high rate of drug resistance mutations (DRMs) and virological breakthrough in over 20% of
HBV infected patients within the first year of therapy [9]. Furthermore, 3TC resistance can
confer cross-resistance to other anti-HBV agents (i.e., emtricitabine, telbivudine and enteca-
vir), which may compromise future anti-HBV and anti-HIV treatment options. Thus, for
HBV/HIV co-infection most expert guidelines recommend dual active NA with higher genetic
barrier to resistance, (i.e., tenofovir disoproxil fumarate or tenofovir alafenamide with combi-
nation Emtricitabine or 3TC) as first line therapy.
In Ethiopia, there is limited information regarding the epidemiology of HBV infection,
genotypes, and drug resistance associated mutations in the context of HIV co-infection. Most
HBV prevalence estimates were based on studies among pregnant women and blood donors
[10–13]. Small cohort studies from the central and northern part of Ethiopia have estimated
the prevalence rate of HBV in HIV positive patients at 3.0%- 5.9% [14–16], and suggested that
CHB may be a significant health concern.
The World Health Organization recommends screening of all HIV patients for viral hepati-
tis, vaccination against HBV in non-immune individuals and providing anti-HBV therapy in
HBV/HIV co-infected patients. However, universal childhood HBV vaccination was not
offered until 2008 in Ethiopia. Although HIV therapy and care is now more widely accessible,
it is not standard practice in Ethiopia for HIV-positive patients to undergo routine testing for
HBV co-infection. In resource-poor settings like Ethiopia, timely updates of the burden and
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correlates for HBV among HIV patients can significantly impact prevention and treatment
strategies. Therefore, the current study aims to investigate the prevalence, HBV genotypes and
HBV drug resistance mutations in a cohort of HIV infected patients in Northwest Ethiopia.
Materials and methods
Study setting and population
This cross-sectional study was conducted at an outpatient HIV antiretroviral (ART) clinic at
the University of Gondar Hospital. The hospital is a tertiary level teaching hospital that pro-
vides in-patient and outpatient medical service to ~5 million people in Northwest Ethiopia.
The HIV ART clinic has been available in the hospital since March 2005, and as of 2014, it is
estimated that 10,000 HIV+ adults were seen, of which 6000 were on combination nucleoside
and non-nucleoside reverse transcriptase inhibitors (NRTI and NNRTI). Testing for HBV and
hepatitis C virus (HCV) co-infection is not standard of care. From March -July 2016, a total of
308 subjects, documented HIV antibody positive, were recruited into the study. Subjects were
excluded if had end-stage acquired immunodeficiency syndrome (AIDS), multisystem illness,
immunosuppression, and severe malnutrition. This study was performed according to the
Declaration of Helsinki and received ethics approval from the institutional review board of
University of Gondar, and Federal Ministry of Science and Technology of Ethiopia. All sub-
jects provided written informed consent to participate.
Collection of clinical data and biological samples
A total of 308 laboratory confirmed HIV-infected adults were selected by a systematic random
sampling technique in an outpatient setting, and provided the necessary information and sam-
ples. The sample size was determined based on a single population formula, considering previ-
ously reported 6% prevalence of HBV [16], with 95% confidence interval (CI), 5% margin of
error. Variables were chosen for inclusion based on their clinical relevance and included age,
sex, marital status, residence, occupation, histories of alcoholism, multiple sexual partner and
unsafe injections, and self-reported history of prior HBV and/or hepatitis C (HCV) testing
and/or treatment. Available clinical data on date of HIV diagnosis, ART, CD4+ T cell count
were extracted through chart review. A total of 8 ml whole blood was drawn for peripheral
blood mononuclear cells (PBMC) and plasma isolation using Ficoll-Hypaque gradient centri-
fugation as described previously [17]. Both plasma and PBMC were shipped to the University
of Calgary, Alberta, Canada in dry ice; with appropriate importation and transportation per-
mits from the Public Health Agency of Canada and the University of Calgary occupational
health and safety office. Samples were stored at -80˚C until analyzed.
HBsAg testing and HBV sequencing analysis
All plasma samples were tested for HBsAg at the Alberta provincial laboratory for public health
using a commercial immunoassay (ARCHITECT; Abbott Diagnostics, Mississauga, Ontario,
Canada). In HBsAg positive cases, HBV genomes were detected following total DNA isolation
from 500μL plasma and/or 1–2 × 106 PBMC by an in-house nested PCR using HBV surface
(S) or core (C) and polymerase (P) gene-specific primers, as previously described [7,18]. All
experiments included parallel mock nucleic acid isolations and PCR water negative controls.
Recombinant HBV DNA or DNA from serum/PBMCs of known HBsAg positive patients was
used as positive controls.
The HBV genotype and drug resistance mutations (DRMs) were determined by direct
Sanger sequencing of S, C and P gene fragments. Samples were sequenced in both directions
Hepatitis B virus in HIV patients
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with universal primers at 3730 XL sequencing system (Applied Biosystem, Foster City, CA,
USA). The sequences were translated for S, C, and P protein and aligned with sequences of
the same genotype to determine putative non-genotypic substitutions. Genbank reference
sequences were used for alignment. For all samples, aa 61–250 of the P/RT and aa 100–160 of
the S antigenic determinant region were analysed. Genotype was determined with the NCBI
genotyping tool (www.ncbi.nlm.nih.gov/projects/genotyping/). Phylogenetic tree was con-
structed using the Maximum Likelihood method and the Tamura 3-parameter model [19].
The bootstrap values based on a 1000 replicates is shown next to the branches. Neighbor-Join
and BioNJ algorithms were used and pairwise distances estimated using the Maximum Com-
posite Likelihood (MCL) approach. All alignments and evolutionary analyses were conducted
using MEGA7 [20]. HBV recombinant analysis was performed by jumping profile Hidden
Markov Model (JpHMM) [21]. All sequences were submitted to GenBank (accession number
pending).
Data analysis
Data analysis was performed using SPSS (v. 20, SPSS Inc., Chicago, IL). Baseline characteristics
of the study participants were reported as percentages or medians with inter-quartile ranges
(IQR). Bivariate and multivariable logistic regression analyses were performed to determine
the association between variables. Odds ratios and 95% confidence intervals were calculated to
determine the strength of association between HBsAg seropositivity and relevant sociodemo-
graphic and clinical factors. P-values less than 0.05 were considered statistically significant for
all analysis.
Results
Summary of clinical and demographic data
Of the 308 HIV positive patients enrolled, 62.7% were female, median age 38 years (range 18–
68, IQR: 27–49), and 43% unable to read and write. Most of the participants (94.2%) were on
ART, and median CD4+T cell count was 405 cells /mm3 (IQR: 75–734). The most common
ART regimen was combination of Zidovudine (AZT)-lamivudine (3TC)–nevirapine (NVP),
followed by TDF-3TC-Efavirenz (EFV). The demographic and baseline characteristics of the
study population are summarized in Table 1.
Prevalence of HBV/HIV coinfection, HBV genotypes and drug resistance
profile
In total, 17 cases (5.5%, 95%CI 2.95–8.08%) tested HBsAg positive (9 male/8 female, median
age 39 years (range, 20–60). All 17 cases were on combination ART with anti-HBV activity (12
on 3TC, and 5 on combination of TDF and 3TC) for a median duration of 6 years (range,
2–10). Median CD4+ T cell count of the co-infected patients was 493 cell/mm3 (range, 83–
1065) (Table 2).
We were able to successfully PCR amplify and do sequence analysis of HBV genomes in 13/
17 HBsAg positive patients. Phylogenetic analysis of these samples revealed that 53.8% (7/13)
of the patients were infected with HBV genotype A, the remaining were genotype D (15.4%),
genotype E (15.4%), and others (15.4%) (Table 3). Representative phylogenetic trees of the iso-
lates are indicated in “S1 and S2 Figs”.
Analysis of HBV P/reverse transcriptase region sequence displayed multiple variants at resi-
dues associated with 3TC drug resistance (i.e. rtV173L, rtL180M, and/or rtM204V) in 7/13
HBV/HIV co-infected patients tested. The most frequent HBV DRM found was rtL180M
Hepatitis B virus in HIV patients
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Table 1. Sociodemographic and clinical characteristics of study subjects at ART clinic of the Univer-
sity of Gondar Hospital.
Characteristics Frequency (%), N = 308
Sex
Male 115(37.3)
Female 193(62.7)
Age (years)
Median(IQR) 38(11.0)
Range (min-max) 50(18–68)
Education
Illiterate 132(42.9)
Elementary 64(20.8)
Secondary and above 112(36.4)
On ART 290(94.2)
ART compliance
Yes 272(93.8)
No 18(6.2)
CD4 T Cell count, Median (IQR) 405 (75–734)
Platelets Count, Median (IQR) 269(165–373)
Rx for Liver disease, n(%) 21(6.8)
Family History of liver diseases, n (%) 7(2.3)
IQR: interquartile range; ART: antiretroviral therapy; Rx: treatment
https://doi.org/10.1371/journal.pone.0190149.t001
Table 2. Clinical and virological characteristics of HBV/HIV co-infected patients (n = 17).
ID Age/sex HBV genotype CD4+ T cella PLT count Anti-HBV agent ART durationb DR Mutations WHO stage
HP14 49/M - 730 531 3TC 7 - I
HP22 38/M A 224 134 3TC 6 rtV173L, rtL180M,rtM204V I
HP32 60/F A 583 260 TDF, 3TC 3 rtV173L, rtL180M,rtM204V I
HP51 37/F A 493 355 3TC 8 rtV173L, rtL180M,rtM204V I
HP64 52/M A 209 222 TDF, 3TC 4 rtL180M I
HP82 39/M E 83 234 TDF, 3TC 6 WT I
HP95 40/F E 640 265 3TC 3 rtV173L, rtL180M,rtM204V I
HP106 39/M - 712 147 3TC 9 - I
HP113 39/F C 483 278 3TC 8 rtV173L, rtL180M,rtM204V I
HP123 28/M A 206 92 3TC 5 rtV173L, rtL180M,rtM204V I
HP141 24/F A 125 272 TDF, 3TC 2 WT I
HP169 37/F D 390 377 3TC 9 WT I
HP193 43/M - 262 184 3TC 10 - I
HP248 30/F G 619 211 3TC 5 WT III
HP258 35/M A 666 305 3TC 2 WT I
HP259 35/M - 1065 234 TDF, 3TC 3 - I
HP268 39/F D 593 388 3TC 7 WT I
3TC, Lamivudine; TDF, Tenofovir, PLT, Platelets count (x 103/mL); DR, drug resistance;
aCD4+T cell count (Cell/μl);
b ART duration (in year)
https://doi.org/10.1371/journal.pone.0190149.t002
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(53.8%), followed by rtV173L (46.2%), and rtM204V (46.2%). Of note, 5 out of 7 patients with
DRMs were receiving 3TC as the only anti-HBV agent (Table 2). However, the classical vac-
cine escape mutation G145R was not detected.
Risk factors for HBsAg seropositivity
Binary and multivariable logistic regression analysis was performed to determine sociodemo-
graphic and other risk factors for HBV seropositivity (S1 Table). Variables like age, sex, resi-
dence, occupation, current CD4+ T lymphocytes count, alcohol abuse, unsafe injection,
tattooing, multiple sexual partner, history of sharing sharp objects, WHO stage, HAART sta-
tus, HAART regimen, and HAART duration were included in the analysis. Patients with a his-
tory of sharing sharp objects (razors, and objects for skin piercing) were more likely to be
HBsAg positive (AOR 3.4, 95% CI 0.6–19.6), as well as alcohol abuse (AOR 2.3, 95% CI 0.72–
7.32), and having multiple sexual partner (95% CI 0.8–8.04, AOR 2.5).
Discussion
Hepatitis B is common among persons living with HIV owing to their common transmission
modes, risk factors, and overlapping endemicity. Co-infections are associated with increased
morbidity and mortality than those caused by either HIV or HBV alone [2–6]. Thus, data on
the proportion of HBV infection, genotypes and DRMs among HIV patients, especially in
HIV high burden settings like Ethiopia, would inform policy makers for prevention, treatment,
and control of HBV/HIV co-infection. In this study, we found the prevalence of HBV to be
5.5%, which was very similar with 3.0%-5.9% rates found in previous studies from Ethiopia
[14–16]. Yet, it is lower when compared with the 9.7% HBV/HIV co-infection rate in South
Africa, 16.7% in Ghana, and 20.4% in Malawi [22–24]. These could be due to differences in the
Table 3. Summary of clinical and demographic characteristics of the 17 HBV/HIV co-infected patients
at the University of Gondar Hospital, March-July, 2016.
Variables N = 17
Sex
Male 9(52.9)
Female 8(47.1)
Age
Median, years(Range) 39 (24–60)
CD4 T cell count,
Median, (Range) 493 (83–1065)
% On ART with anti-HBV, n (%)
Lamivudine (3TC) 12 (70.6)
Tenofovir (TDF) + 3TC 5 (29.4)
ART duration, year
Mean (SD) 5.7 (2.6)
Median (Range) 6 (2–10)
Genotype, n (%)
A 7 (41.2)
D 2 (11.8)
E 2 (11.8)
C 1 (5.9)
G 1(5.9)
Not Determined 4 (23.5)
https://doi.org/10.1371/journal.pone.0190149.t003
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study population and prevailing risk factors. We do not have data to date on HBV core anti-
body and HBV surface antibody in this cohort, thus it is possible that some of these study sub-
jects could have natural or vaccine induced immunity to the HBV. However, universal
vaccination was not introduced in Ethiopia until 2008 and is not yet widely implemented in
rural areas.
It is noteworthy that 94% of the study participants were on ART treatment with at least one
HBV-active agent for a minimum of six months (median CD4 T cell count was 493 cell/μl).
Hence, it appears that with ART restoration of immunity, subjects could have spontaneously
cleared HBsAg following recovery from acute HBV infection. In this scenario, these individu-
als may carry occult HBV infection (i.e., HBsAg negative, anti-HBc and/or anti-HBs positive,
with low-level HBV DNA in plasma) [25]. In the current study, we randomly tested 12 HBsAg
seronegative samples and observed that 5/12 were positive for anti-HBc (data not shown). This
observation suggests that the burden of chronic as well as occult HBV in this cohort could be
much higher than the figure in this report, and is an area of further study.
We found a marginally higher prevalence of HBV/HIV co-infection in male patients (i.e.,
7.8% vs 4.1% in females). This was in agreement with a number of previous studies [15, 16,
26], although reasons for such gender disparity are unclear. This study also found that subjects
with a history of alcohol abuse, sharing objects for skin piercing, and multiple sexual partners
had slightly higher likelihood of HBsAg seropositivity [16, 26, 27]. Therefore, it is possible that
gender differences in behavioural risk factors could contribute to higher prevalence of HBV
co-infection in male patients.
It is recommended that all HBV/HIV co-infected patients receive highly active ART with
dual anti-HIV/HBV activity, irrespective of their CD4+ T cell counts. The combination of
TDF with 3TC/ FTC is recommended as a highly effective first-line treatment for HBV; but
treatment with 3TC as the only anti-HBV agent in ART is not recommended due to the risk of
anti-HBV resistance development [28, 29]. In this regard, we found that ~29.4% (5/17) of
HBV/HIV co-infected patients in our setting were treated with ART containing 3TC and TDF,
and 12/17 was on ART with 3TC as the only HBV-active agent. We found that more than half
of these patients, for whom sequence data were available, had 3TC selected DRMs (rtV173L,
rtL180M, and rtM204V). This rate is much higher than the 3TC resistance mutations rates
(<15%) reported from other sub-Sahara African countries [30, 31]. The discrepancy between
our finding and the other African cohorts could be related to differences in time on HAART,
the timing of HBV infection in relation to HIV-1 infection and/or to factors related to study
design. In light of these, our observation has important implications for current HBV manage-
ment in HIV patients and underscores the need for screening all HIV patients for HBV prior
to initiation of ART.
In this study, we have also determined HBV genotypes circulating among HBV/HIV co-
infected subjects to identify the impact of different genotypes on clinical outcomes such as
development of 3TC resistance mutations. Currently, about ten HBV genotypes (A-J) have
been identified, with genotype A, D, and E circulating in Sub-Sahara Africa [32]. The knowl-
edge of HBV genotypes has gained special attention, because it is essential in predicting HBV
infectivity, transmission mode, response to treatment, and disease progression [33–35]. It
has been observed that African patients are at risk of aggressive HCC development at a
young age, even if non-cirrhotic. This increased HCC risk has been attributed to environ-
mental factors such as the presence of contaminating dietary aflatoxins, and viral factors
such as specific HBV genotype (i.e., Genotype A) [36–38]. In the current study, we found
that 7/13 of the co-infected patients carry HBV genotype A, but interestingly the others
included genotype C, D, E, and G. This finding confirms and expands the previous reports
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from Ethiopia that reported HBV genotype A to be the predominant genotype circulating in
the country [39].
In the current study, all HBV/HIV co-infected patients were on ART with anti-HBV activ-
ity and likely had a low level of HBV DNA, hence it was not possible to obtain sequence data
in 4 cases found to be HBsAg positive. Additionally, explanatory variables such as family his-
tory of liver disease, history of sharing sharp objects, and ART compliance were collected by
questionnaire and may introduce the possibility of recall bias. Nevertheless, the gap identified
by our study in the current management of HBV in HIV patients may have an implication for
the public health policy makers and merits further investigations.
In conclusion, our study found that 5.5% of HIV patients followed in Gondar University
Hospital, Ethiopia were HBsAg positive. Most were receiving the first generation anti-HBV
therapy with a low genetic barrier to resistance, and several carried mutations associated with
anti-HBV (3TC) drug resistance. These data underscore the importance of integrating HBV
screening to the HIV treatment guidelines for better management and prevention of HBV-
related liver disease.
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S1 Fig. Neighbor-joining phylogenetic tree based on P/RT gene from HBV-HIV co-
infected Ethiopian patients and reference sequences representing all known HBV subgeno-
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(TIF)
S1 Table. Multivariate analysis of associated factors for HBsAg seropositivity among HIV
patients.
(DOCX)
Acknowledgments
The authors are very grateful to Sheila Braun for her support in sample testing and global
health office of the University of Calgary for their advice in coordination of various activities.
Our deep gratitude also extends to the University of Gondar Teaching Hospital physicians,
counseling nurses and ART staffs for their kind cooperation during data collection.
Author Contributions
Conceptualization: Tekalign Deressa, Debasu Damtie, Shitaye Alemu, Guido van Marle,
Carla S. Coffin.
Data curation: Tekalign Deressa, Debasu Damtie, Kevin Fonseca, Shan Gao, Ebba Abate,
Yetemwork Aleka, Mark G. Swain, Guido van Marle, Carla S. Coffin.
Formal analysis: Tekalign Deressa, Debasu Damtie, Kevin Fonseca, Shan Gao, Ebba Abate,
Shitaye Alemu, Yetemwork Aleka, Mark G. Swain, Guido van Marle, Carla S. Coffin.
Funding acquisition: Tekalign Deressa, Debasu Damtie, Ebba Abate, Shitaye Alemu.
Hepatitis B virus in HIV patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0190149 December 27, 2017 8 / 11
Investigation: Tekalign Deressa, Kevin Fonseca, Shan Gao, Ebba Abate, Shitaye Alemu,
Yetemwork Aleka, Mark G. Swain, Guido van Marle, Carla S. Coffin.
Methodology: Tekalign Deressa, Shan Gao, Ebba Abate, Shitaye Alemu, Yetemwork Aleka.
Project administration: Tekalign Deressa.
Resources: Kevin Fonseca, Ebba Abate, Mark G. Swain, Guido van Marle, Carla S. Coffin.
Supervision: Mark G. Swain, Guido van Marle, Carla S. Coffin.
Writing – original draft: Tekalign Deressa.
Writing – review & editing: Tekalign Deressa, Debasu Damtie, Kevin Fonseca, Shan Gao,
Ebba Abate, Shitaye Alemu, Yetemwork Aleka, Mark G. Swain, Guido van Marle, Carla S.
Coffin.
References
1. World health organization: WHO hepatitis B.htm. WHO, Geneva, Switzerland. http://www.
WHOhepatitisB.htm. Accessed on 22 June 2015.
2. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatol 2009; 49:S138–145.
3. Liaw YF, Brunetto MR, Hadziyannis S. The natural history of chronic HBV infection and geographical
differences. Antivir Ther 2010; 15 Suppl 3:25–33.
4. Bodsworth N, Donovan B, Nightingale N. The effect of concurrent human immunodeficiency virus infec-
tion on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989; 160(4): 577–582. PMID:
2571646
5. Alter MJ. Epidemiology of viral Hepatitis and HIV co-infection. J hepatol 2006; 44:s6–9. https://doi.org/
10.1016/j.jhep.2005.11.004 PMID: 16352363
6. Hoffman J, Thio L. Clinical implication of HIV and HBV co-infection in Asia and Africa. Lancet Infect Dis
2007; 7(6): 402–409. https://doi.org/10.1016/S1473-3099(07)70135-4 PMID: 17521593
7. Coffin CS, Osiowy C, Myers RP, Gill MJ. Virology and clinical sequelae of long-term antiviral therapy in a
North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected
patients. J Clin Virol 2013; 57(2):103–8. https://doi.org/10.1016/j.jcv.2013.02.004 PMID: 23465393
8. Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Muñoz A, et alL. HIV-1, hepatitis B virus, and
risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921–1926.
PMID: 12493258
9. Rusine J, Ondoa P, Asiimwe-Kateera B, Boer KR, Uwimana JM, Mukabayire O,et al. High seropreva-
lence of HBV and HCV infection in HIV-infected adults in Kigali, Rwanda. PLoS ONE 2013; 8: e63303.
https://doi.org/10.1371/journal.pone.0063303 PMID: 23717409
10. Umare A, Seyoum B, Gobena T, Haile Mariyam T. Hepatitis B Virus Infections and Associated Factors
among Pregnant Women Attending Antenatal Care Clinic at Deder Hospital, Eastern Ethiopia. PLoS
ONE 2016; 11(11): e0166936. https://doi.org/10.1371/journal.pone.0166936 PMID: 27898721
11. Gebreegziabher D, Asfeha GG, Gebreyesus HA. Seroprevalence of hepatitis B virus surface antigen
(HBsAg) among clients visiting ‘Tefera Hailu’ memorial hospital, Sekota, Northern Ethiopia. BMC Infect
Dis 2016; 16:383. https://doi.org/10.1186/s12879-016-1744-3 PMID: 27503445
12. Tessema B, Yismaw G, Kassu A, Amsalu A, Mulu A, Emmrich F, et al. Sero-prevalence of HIV, HBV,
HCV and syphilis infections among blood donors at Gondar University teaching hospital, northwest Ethi-
opia: declining trends over a period of five years. BMC Infect Dis 2010; 10:111.9. https://doi.org/10.
1186/1471-2334-10-111 PMID: 20459703
13. Zenebe Y, Mulu W, Yimer M, Abera B. Sero-prevalence and risk factors of hepatitis B virus and human
immunodeficiency virus infection among pregnant women in Bahir Dar city, northwest Ethiopia: a cross
sectional study. BMC Infect Dis 2014; 14:118. https://doi.org/10.1186/1471-2334-14-118 PMID:
24580859
14. Manyazewal T, Sisay Z, Biadgilign S, Abegaz WE. Hepatitis B and hepatitis C virus infections among
antiretroviral-naive and -experienced HIV co-infected adults. J Med Microbiol 2014; 63: 742–747.
https://doi.org/10.1099/jmm.0.063321-0 PMID: 24757219
15. Wondimeneh Y, Alem M, Asfaw F, Belyhun Y. HBV and HCV seroprevalence and their correlation with
CD4 cells and liver enzymes among HIV positive individuals at University of Gondar Teaching Hospital,
Northwest Ethiopia. Virology J 2013; 10:171.
Hepatitis B virus in HIV patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0190149 December 27, 2017 9 / 11
16. Weldemhret L, Asmelash T, Belodu R, Gebreegziabiher D. Sero-prevalence of HBV and associated
risk factors among HIV positive individuals attending ART clinic at Mekelle hospital, Tigray, Northern
Ethiopia. AIDS Res Ther 2016; 13:6. https://doi.org/10.1186/s12981-016-0090-2 PMID: 26855663
17. Coffin CS, Mulrooney-Cousins PM, van Marle G, Roberts JP, Michalak TI, Ter-rault NA. Hepatitis B
virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylac-
tic therapy. Liver Transpl 2011; 17: 955–562. https://doi.org/10.1002/lt.22312 PMID: 21462295
18. Coffin CS, Osiowy C, Gao S, Nishikawa S, Meer FV, Marle GV. Hepatitis B virus (HBV) variants fluctu-
ate in paired plasma and peripheral blood mononuclear cells among patient cohorts during different
chronic hepatitis B (CHB) disease phases. J Viral Hepat 2015; 22 (4): 416–426 https://doi.org/10.1111/
jvh.12308 PMID: 25203736
19. Tamura K. (1992). Estimation of the number of nucleotide substitutions when there are strong transi-
tion-transversion and G + C-content biases. Molecular Biology and Evolution 9:678–687. PMID:
1630306
20. Kumar S., Stecher G., and Tamura K. (2016). MEGA7: Molecular Evolutionary Genetics Analysis ver-
sion 7.0 for bigger datasets. Molecular Biology and Evolution 33:1870–1874. https://doi.org/10.1093/
molbev/msw054 PMID: 27004904
21. Schultz AK, Bulla I, Abdou-Chekaraou M, Gordien E, Morgenstern B, Zoaulim F, Deny P, Stanke M.
2012. JpHMM: Recombination analysis in viruses with circular genomes such as the hepatitis B virus.
Nucleic Acids Res 40:W193–W198. https://doi.org/10.1093/nar/gks414 PMID: 22600739
22. Matthews PC, Beloukas A, Malik A, Carlson JM, Jooste P, Ogwu A, et al. Prevalence and characteris-
tics of hepatitis B virus (HBV) coinfection among HIV-Positive women in South Africa and Botswana.
PLoS One 2015; 10:e0134037. https://doi.org/10.1371/journal.pone.0134037 PMID: 26218239
23. Geretti AM, Patel M, Sarfo FS, Chadwick D, Verheyen J, Fraune M, et al. Detection of highly prevalent
hepatitis B virus coinfection among HIV seropositive persons in Ghana. J Clin Microbiol 2010; 48
(9):3223–30. https://doi.org/10.1128/JCM.02231-09 PMID: 20631103
24. Nyirenda M, Beadsworth M, Stephany P, Hart C, Hart I, Munthali C, et al: Prevalence of infection with
hepatitis B and C virus and co-infection with HIV in medical inpatients in Malawi. J Infect Dis 2008;
57:72–77.
25. Coffin CS, Mulrooney-Cousins PM, Osiowy C, van der Meer F, Nishikawa S, Michalak TI, van Marle G,
Gill MJ. Virological characteristics of occult hepatitis B virus in a North American cohort of human immu-
nodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy. J Clin Virol 2014; 60
(4):347–53. https://doi.org/10.1016/j.jcv.2014.04.021 PMID: 24881491
26. Archampong T, Lartey M, Sagoe KW, Obo-Akwa A, Kenu E, Gillani FS, et al. Proportion and factors
associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected
Ghanaian patients. BMC Infect Dis 2016; 16:14. https://doi.org/10.1186/s12879-016-1342-4 PMID:
26759172
27. Burnett RJ, Francois G, Kew MC, Leroux-Roels G, Meheus A, Hoosen AA, et al. Hepatitis B virus and
human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver
Int 2005; 25:201–213. https://doi.org/10.1111/j.1478-3231.2005.01054.x PMID: 15780040
28. Centers for Disease Control and Prevention. Guidelines for Prevention and Treatment of Opportunistic
Infections in HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes
of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. April 10,
2009.
29. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long-term incidence of
hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatol
1999; 30(5):1302–6.
30. Kouanfack C, Aghokeng AF, Mondain AM, Bourgeois A, Kenfack A, Mpoudi-Ngole´ E, et al. Lamivudine-
resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic
in Cameroon. Antivir Ther 2012; 17: 321–326. https://doi.org/10.3851/IMP1911 PMID: 22290198
31. Stewart B, Jobarteh J, Sarge-Njie R, Alabi A, Peterson K, Peterson K, et al. Emergence of HBV resis-
tance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa. BMC Res
Notes 2011; 4: 561. https://doi.org/10.1186/1756-0500-4-561 PMID: 22195774
32. Norder H, Courouce´ A-M, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, et al. Genetic diversity
of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervir-
ology 2004; 47(6):289–309. https://doi.org/10.1159/000080872 PMID: 15564741
33. McMahon BJ. The influence of hepatitis B virus genotype and sub genotype on the natural history of
chronic hepatitis B. Hepatol Int 3:334–342. https://doi.org/10.1007/s12072-008-9112-z PMID:
19669359
Hepatitis B virus in HIV patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0190149 December 27, 2017 10 / 11
34. Kramvis A, Kew MC. 2007. Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associ-
ations of genotypes. Hepatol Res 37:S9–S19. https://doi.org/10.1111/j.1872-034X.2007.00098.x
PMID: 17627641
35. Buti M, Rodriguez-Frias F, Jardi R, Esteban R. Hepatitis B virus genome variability and disease pro-
gression: the impact of pre-core mutants and HBV genotypes. J Clin Virol 2005; 34(Suppl 1):S79–82.
36. Kew MC, Kramvis A, Yu MC, Arakawa K, Hodkinson J. Increased hepatocarcinogenic potential of hepa-
titis B virus genotype A in Bantu-speaking sub-saharan Africans. J Med Virol. 2005; 75(4):513–21.
https://doi.org/10.1002/jmv.20311 PMID: 15714494
37. Shimakawa Y, Lemoine M, Njai HF, Bottomley C, Ndow G, Goldin RD, et al. Natural history of chronic
HBV infection in West Africa: a longitudinal population-based study from The Gambia. Gut. 2016;
65(12):2007–2016 https://doi.org/10.1136/gutjnl-2015-309892 PMID: 26185161
38. Kew Michael C. Hepatocellular carcinoma in African Blacks: Recent progress in etiology and pathogen-
esis. World J Hepatol 2010; 2(2): 65–73. https://doi.org/10.4254/wjh.v2.i2.65 PMID: 21160975
39. Hundie GB, Raj VS, Michael DG, Pas SD, Osterhaus AD, Koopmans MP, Smits SL, Haagmans BL.
Molecular epidemiology and genetic diversity of hepatitis B virus in Ethiopia. J Med Virol 2016;
88(6):1035–43. https://doi.org/10.1002/jmv.24437 PMID: 26629781
Hepatitis B virus in HIV patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0190149 December 27, 2017 11 / 11
